Tests JZP926 capsule for juvenile myoclonic epilepsy in people aged 10 and older

Trial details

Who runs it

Jazz Pharmaceuticals

Trial code

NCT07723963

Record updated

2 November 2026

Original description

This study is being conducted to evaluate the safety and efficacy of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).Read full original descriptionShow less

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of JZP926 in Participants Aged 10 Years and Older for the Treatment of Juvenile Myoclonic Epilepsy

This study is being conducted to evaluate the safety and efficacy of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).

Inclusion: Participants are eligible to be included in the study only if all of the following criteria apply:; Is ≥ 10 years of age at the time of screening; Has a diagnosis of JME per ILAE criteria as specified in the protocol; Has at least 4 myoclonic seizure days per 28 days historical seizure frequency.

Exclusion: Has a concurrent, confirmed diagnosis of non-epileptic seizures or events that can confound the assessment of the efficacy measures, in the opinion of the investigator; Has a history of status epilepticus in the 3 months prior to screening; Is currently treated with Epidiolex or recently received treatment with Epidiolex within 28 days prior to screening; Is currently using or has used recreational or medicinal cannabis, cannabinoid/CBD based medications, products, or supplements (botanical or synthetic) within 28 days prior to screening; Is unwilling or unable to abstain from recreational or medicinal cannabis, cannabinoid/CBD based medications, products, or supplements (botanical or synthetic) for the duration of the study; Presence of seizure types other than GTC, myoclonic, and absence seizures; If historical MRI has been performed, participant's MRI reveals a cause of epilepsy other than JME; The etiology of the participant's seizures is a progressive neurologic disease; Has clinically unstable or progressive epilepsy; Has clinically significant unstable medical condition(s), other than epilepsy, including unstable psychiatric disorders; History of suicidal behavior, current suicidal risk as determined from history, or presence of active suicidal ideation as indicated by a positive response to Item 4 or Item 5 on the C-SSRS or is considered at risk of suicide or self-harm based on the clinical judgement of the investigator following interview with the participant and/or caregiver; Has known or suspected hypersensitivity to cannabinoids or any of the excipients of the study intervention; Participants are excluded from the study if any of the following criteria apply:; Has a body weight < 20 kg or > 150 kg.

ClinicalTrials.gov NCT07723963